Pharmacosmos Group Acquires Boston Based Clinical Stage AbFero Pharmaceuticals, Inc

Pharmacosmos Group Acquires Boston Based Clinical Stage AbFero Pharmaceuticals, Inc

Pharmacosmos Group, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced the acquisition of AbFero Pharmaceuticals, Inc., a Boston based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload. Pharmacosmos A/S, through a US subsidiary, will acquire all assets of AbFero Pharmaceuticals under a share purchase agreement for a total consideration of up to $225M when combining upfront payments, regulatory and commercial milestones, and royalties. "Given Pharmacosmos's research focus and expertise within iron metabolism and its international commercial presence, the acquisition of AbFero constitutes a perfect strategic fit. We look forward to completing the development of SP-420 in order to bring new treatment options for patients suffering from transfusional iron overload and other iron mediated conditions," said Lars Christensen, CEO of Pharmacosmos A/S. "The role of iron in disease has been vastly underappreciated. As a leader in iron metabolism disorders, Pharmacosmos is uniquely positioned to realize the full potential of our chelation platform," said AbFero CEO and Co-Founder Thomas X. Neenan. "We are grateful to Prof. Ray Bergeron of the University of Florida, the inventor of our technology platform, and to our management and investors for their commitment to our mission. We now look forward to joining forces with Pharmacosmos to deliver much-needed therapeutic options to patients." ABOUT IRON CHELATION THERAPY AND SP-420 Patients with hematological diseases such as

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!